SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW

Silexion Therapeutics Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.15+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $105.17K
P/E (TTM): 0.0
Dividend yield: –

Silexion Therapeutics Corp cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Stock-Based Compensation	0.13	5.86	0.13
Other Non-Cash Items	-0.34	1.05	-0.32
Change in Accounts Payable	-0.14	0.61	0.08
Operating Cash Flow	-11	-8.40	-4.53
Capital Expenditures	-0.01	-0.02	-0.01
Sale of Property, Plant & Equipment	–	0	0.08
Purchase of Investments	-0.01	0	–
Sale & Maturity of Investments	–	0	0.51
Investing Cash Flow	-0.01	-0.02	0.57
Financing Cash Flow	16	5.10	0.52
Foreign Exchange Rate Adjustments	0.00	-0.06	-0.23
Free Cash Flow	-11	-8.42	-4.54
Interest Paid	0.01	0.03	0

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 1718.9%

Financial strength

Current ratio: 0.94
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 56.1%

Valuation

P/E ratio: 0.0
Price to sales: –
Price to book: 2.39
Dividend yield: –